Covance is launching Xcellerate, a new methodology designed to help optimize clinical trial performance in order to improve quality, reduce waste and decrease trial timelines. According to the company, the Xcellerate methodology enables Covance to make custom recommendations for site, investigator and geographic selections for every program it manages, and to help enhance clinical trial design and execution. Xcellerate is part of Covance’s approach to clinical trial management and is not a stand-alone service offering.

“Biopharmaceutical companies have come under increasing pressure in recent years to reduce their R&D spending and re-invigorate their drug development pipelines,” said Rick Cimino, group president, Clinical Development Services, Covance. “We believe that Covance, through Xcellerate, can deliver high value to our clients by improving time-to-market speeds that ultimately should help them bring new medicines to patients faster.”